{"title":"不同临床形式多发性硬化症的认知障碍","authors":"Behidzhe Sadarzanska-Terzieva, Silvia Tsvetkova","doi":"10.5272/jimab.2024302.5559","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of the study is to investigate cognitive impairment (CI) in patients with different clinical forms of Multiple Sclerosis (MS) and to propose a suitable cognitive evaluation based on available tools for diagnosis and monitoring purposes. Materials and Methods: The following tests were used: Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), Expanded Disability Status Scale (EDSS) and Magnetic Resonance Tomography 1.5Т (МRТ) in 60 consecutive patients; 22 were with first demyelination episode and 38 with MS. The control group of 40 healthy persons matched for sex, age and years of education. The follow-up period is three years. Results: The average screening values of PASAT, SDMT, BVSMT-R are considerably lower (р<0.05) in MS patients compared to the controls and CIS patients. Point's number in the progressive forms in comparison with RRMS is reliably smaller. There was no significant difference in results between SPMS and PPMS patients at screening (р>0.05). In the 3rd year, there is a significant cognitive progression in all studied groups and for all tests (р<0.05). Conclusion: The use of a neuropsychological screening test is a valuable method for registering CI in patients with relapsing-remitting course, as well as in patients with a progressive course of the disease. We recommend the SDMT for screening annual follow-up because it is easy to apply, validate and reliably report the progression of CI. In patients with visual disturbances and with arm weakness, it is better to use PASAT, taking into account the level of education and depression.","PeriodicalId":339756,"journal":{"name":"Journal of IMAB - Annual Proceeding (Scientific Papers)","volume":"11 16","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COGNITIVE IMPAIRMENT IN DIFFERENT CLINICAL FORMS OF MULTIPLE SCLEROSIS\",\"authors\":\"Behidzhe Sadarzanska-Terzieva, Silvia Tsvetkova\",\"doi\":\"10.5272/jimab.2024302.5559\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: The aim of the study is to investigate cognitive impairment (CI) in patients with different clinical forms of Multiple Sclerosis (MS) and to propose a suitable cognitive evaluation based on available tools for diagnosis and monitoring purposes. Materials and Methods: The following tests were used: Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), Expanded Disability Status Scale (EDSS) and Magnetic Resonance Tomography 1.5Т (МRТ) in 60 consecutive patients; 22 were with first demyelination episode and 38 with MS. The control group of 40 healthy persons matched for sex, age and years of education. The follow-up period is three years. Results: The average screening values of PASAT, SDMT, BVSMT-R are considerably lower (р<0.05) in MS patients compared to the controls and CIS patients. Point's number in the progressive forms in comparison with RRMS is reliably smaller. There was no significant difference in results between SPMS and PPMS patients at screening (р>0.05). In the 3rd year, there is a significant cognitive progression in all studied groups and for all tests (р<0.05). Conclusion: The use of a neuropsychological screening test is a valuable method for registering CI in patients with relapsing-remitting course, as well as in patients with a progressive course of the disease. We recommend the SDMT for screening annual follow-up because it is easy to apply, validate and reliably report the progression of CI. In patients with visual disturbances and with arm weakness, it is better to use PASAT, taking into account the level of education and depression.\",\"PeriodicalId\":339756,\"journal\":{\"name\":\"Journal of IMAB - Annual Proceeding (Scientific Papers)\",\"volume\":\"11 16\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of IMAB - Annual Proceeding (Scientific Papers)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5272/jimab.2024302.5559\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of IMAB - Annual Proceeding (Scientific Papers)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5272/jimab.2024302.5559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在调查不同临床形式的多发性硬化症(MS)患者的认知障碍(CI),并根据现有的诊断和监测工具提出合适的认知评估方法。材料与方法:使用了以下测试对 60 名连续患者进行了步调听觉连续加法测验(PASAT)、符号数字模型测验(SDMT)、简明视觉空间记忆测验-修订版(BVMT-R)、残疾状况扩展量表(EDSS)和磁共振断层扫描 1.5Т(МRТ),其中 22 名患者为首次脱髓鞘发作,38 名患者为多发性硬化症。对照组由 40 名健康人组成,他们的性别、年龄和受教育年限均匹配。随访期为三年。结果显示PASAT、SDMT、BVSMT-R 的平均筛查值明显偏低(р0.05)。在第三年,所有研究组的所有测试结果均显示认知能力明显下降(р<0.05)。结论使用神经心理学筛查测试是对复发-缓解型患者以及进展型患者进行 CI 登记的重要方法。我们推荐将 SDMT 用于年度随访筛查,因为它易于应用、验证并能可靠地报告 CI 的进展情况。对于视力障碍和手臂无力的患者,最好使用 PASAT,同时考虑到患者的受教育程度和抑郁程度。
COGNITIVE IMPAIRMENT IN DIFFERENT CLINICAL FORMS OF MULTIPLE SCLEROSIS
Purpose: The aim of the study is to investigate cognitive impairment (CI) in patients with different clinical forms of Multiple Sclerosis (MS) and to propose a suitable cognitive evaluation based on available tools for diagnosis and monitoring purposes. Materials and Methods: The following tests were used: Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), Expanded Disability Status Scale (EDSS) and Magnetic Resonance Tomography 1.5Т (МRТ) in 60 consecutive patients; 22 were with first demyelination episode and 38 with MS. The control group of 40 healthy persons matched for sex, age and years of education. The follow-up period is three years. Results: The average screening values of PASAT, SDMT, BVSMT-R are considerably lower (р<0.05) in MS patients compared to the controls and CIS patients. Point's number in the progressive forms in comparison with RRMS is reliably smaller. There was no significant difference in results between SPMS and PPMS patients at screening (р>0.05). In the 3rd year, there is a significant cognitive progression in all studied groups and for all tests (р<0.05). Conclusion: The use of a neuropsychological screening test is a valuable method for registering CI in patients with relapsing-remitting course, as well as in patients with a progressive course of the disease. We recommend the SDMT for screening annual follow-up because it is easy to apply, validate and reliably report the progression of CI. In patients with visual disturbances and with arm weakness, it is better to use PASAT, taking into account the level of education and depression.